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Abstract:
Objective: This study was performed to detect the expression of  vitamin D receptor (VDR) and cytochrome P450, family 24, 
subfamily A, polypeptide 1 (CYP24A1) in 24 end stage renal disease (ESRD) patients and 24 healthy controls.
Method: In this study, 24 ESRD patients and 24 healthy controls were included.
Results: In our study, the levels of  VDR in patients with ESRD were reduced when compared with those from healthy con-
trols (5.20±0.32 vs 8.59±1.03; P﹤0.01). However, the levels of  CYP24A1 in ESRD patients were increased than those from 
healthy controls (50.18±21 vs 7.78±1.31; P﹤0.01). Correlation analysis showed that VDR levels were negatively correlated with 
CYP24A1 (r=-0.723; P﹤0.01).
Conclusion: VDR levels were reduced and CYP24A1 levels were increased in patients with ESRD, and VDR levels were nega-
tively correlated with CYP24A1.
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Introduction
End stage renal disease (ESRD) represents a clinical con-
dition in which there has been an irreversible loss of  en-
dogenous renal function. ESRD is an increasing problem 
worldwide and is a major health problem associated with 
very high morbidity and mortality1,2. Patients with ESRD 
must receive a kidney transplant or live on dialysis1,3.  Re-
duction in serum 1,25 (OH) (2)D level plays an important 
role in the pathophysiology of  altered bone and miner-
al metabolism among patients with advanced stages of  
chronic kidney disease (CKD). Alterations in vitamin D 
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metabolism are included. Many adverse events have been 
associated with vitamin D deficiency or lack of  vitamin D 
receptor (VDR) activation both in the general population 
and CKD patients4.
Vitamin D regulates the action of  hormone responsive 
genes, is involved in cell cycle regulation, differentiation 
and apoptosis, and plays a role involving the renal dis-
eases acting through the vitamin D receptor (VDR)5. The 
VDR is a nuclear hormone receptor mediating the activity 
of  vitamin D hormone6. The major role of  cytochrome 
P450, family 24, subfamily A, polypeptide 1 (CYP24A1) 
is to maintain 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
homeostasis7. In this study, we investigated the levels of  




Object of  study and specimen collection
All patients we enrolled had been diagnosed with ESRD 
at the Department of  Nephrology, Huadu District Peo-
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ple's Hospital, Southern Medical University, Guangzhou, 
China, between March 2014 and October 2014. Relevant 
specimens were taken from 24 ESRD patients with main-
tenance hemodialysis. There were 13 males and 11 fe-
males and the age was 46.88±15.53 years old. 
Furthermore, the control group recruited 24 healthy vol-
unteers without any renal disease. There were 13 males 
and 11 females and the age was 44.08±14.27 years old.
There were no statistically significant differences among 
the above two groups in gender and age (P=0.321 and 
P=1 respectively; Table 1). The study was approved by 
the Ethics Committee of  our Medical Faculty and written 
informed consents were obtained from all patients and 
the healthy controls before study entry.
 
Specimen collection and procession
3ml blood sample was drawn from each ESRD patients 
and healthy controls, and the blood sample was placed 
into a dry and clean tube. Then put it aside at room tem-
perature for 30 minutes until it clotted. After the sample 
was centrifugated at 3000r/min at room temperature for 
5 minutes, 2ml serum was extracted and shifted into an-
other dry and clean tube. The sample was stored in -20oC 
refrigerator for inspection.
 
Detection serum VDR, CYP24A1 levels by ELISA.
Operations were performed strictly in accordance with 
the instruction of  VDR, CYP24A1 ELISA kit (Cusabio, 
Inc., China). Detection steps as follows: all the specimens 
were removed from -20oC refrigerator and balanced to 
room temperature. 10000 pg/m1 standard solution was 
prepared, and followed by serial dilution with sample di-
luent solution and became 400, 200, 100, 50, 25, 12.5, 
6.25 and 0 pg/ml for VDR and 500, 250, 125, 62.5, 31.5, 
15.6 and 0 pg/ml for CYP24A1, respectively. The sample 
diluent solution was taken as the standard of  0 pg/ml, 
and 100μl different concentration of  the above-men-
tioned solutions were taken to fill the first row (Al-Hl) 
in the ELISA plate in accordance with the sequence of  
concentration. Other empty wells were filled with 100μl 
diluent of  serum or urine sample which was diluted by 
1:10. After the incubation in 37°C incubator for 90 min-
utes, we poured away the liquid and filled the holes with 
100μl biotinylated anti-human antibody of  VDR, CY-
P24A1, covered the plate and put into 37°C incubator for 
60 minutes. After the incubation, the plate was washed 
with phosphate-buffered saline (PBS) three times and 
100μl streptavidin labeled horseradish peroxidase (HRP) 
was added into each hole; the plate was covered and put 
into 37oC incubator again for 30 minutes. After washing 
the plate with PBS solution three times and adding 90μl 
color reagent, we put the plate into the incubator for 30 
minutes repeatedly. Finally, 100μl stopping solution was 
added into each well to terminate the reaction. The ab-
sorbance of  the samples was detected at 450 nm by en-
zyme-labeling measuring instrument (Bio-Tek Co., USA) 
and standard curve was scaled to calculate the VDR, CY-
P24A1 levels of  serum specimens.  
 
Statistical analysis
Database by Excel 2003 was established to include all the 
data in our study; statistical description and hypothesis 
test were analyzed by statistical package for the social sci-
ence 13.0 (SPSS 13.0). Statistical description of  the mea-
surement materials were expressed as mean plus or minus 
standard deviation (mean ± SD). The t test with different 
samples was adopted for comparison between groups. 
Pearson correlation coefficient was used to determine the 
relationships between VDR and CYP24A1.P﹤0.05 was 
chosen as the level of  statistical significance.
 
Results
Serum VDR levels in two groups
Compared with the control group’s, levels of  serum VDR 
in ESRD group were significantly lower (5.20±0.32 pg/
ml vs. 46.25±12.87 pg/m1, P﹤0.01; Table 1 and Figure 
1).
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Table 1. The characteristics and the VDR, CYP24A1 expression in two groups 
 
  ESRD (n=24) Control (n=24) P 
Age 46.88±15.53 44.08±14.27 0.321 
Sex (man/female) 13(54.17%)/11(45.83%) 13(54.17%)/11(45.83%) 1.000 
VDR 5.20±0.32 8.59±1.03 ﹤0.01 
CYP24A1 50.18±21 7.78±1.31 ﹤0.01 
 
Serum CYP24A1 levels in two groups
In ESRD group, the levels of  serum CYP24A1 were 
markedly higher than those in control group (50.18±21 
pg/ml vs. 7.78±1.31 pg/ml, P﹤0.01; Table 1 and Figure 
2).
African Health Sciences Vol 16 Issue 2, June 2016 464
Correlation analysis
Significant negative correlation was noted between VDR 
and CYP24A1 (r=-0.664, P﹤0.05).  
Discussion
End stage renal disease (ESRD) is a major health problem 
associated with very high morbidity and mortality. Hemo-
dialysis is one of  the most important treatment measure 
of  renal replacement therapy for ESRD patients. How-
ever, chronic kidney disease-mineral and bone disorders 
(CKD-MBD) ranks among clinically and pathogeneti-
cally significant complications in patients with CKD, and 
CKD-MBD is associated with vascular calcification and 
abnormal electrolytes that lead to cardiovascular disease 
and mortality8-10. In this study, we detected the association 
of  VDR with CYP24A1, and their expressions in ESRD 
patients.
In our study, we found that the VDR levels in ESRD 
patients were reduced and the CYP24A1 levels were in-
creased in ESRD patients. In previous, vitamin D defi-
ciency was regarded as one of  the most important char-
acteristics for the patients with ESRD. VDR activators 
can improve the CKD-MBD and vascular calcification. 
However, the VDR level in ESRD patients in serum was 
rarely studied. In previous, Denda et al11 conducted a 
study in rats and found that account for the decrease in 
VDR content in parathyroid glands of  uremic rats and 
that treatment with 1,25-D3 or OCT prevents this de-
crease ameliorating the development of  secondary hyper-
parathyroidism. Fukuda et al12 investigated VDR distri-
bution in surgically-excised parathyroids obtained from 
chronic dialysis patients by immunohistochemistry, and 
found that the decreased VDR density in parathyroids 
might contribute to the progression of  secondary hyper-
parathyroidism and to the proliferation of  parathyroid 
cells that was seen in uremia.There were lots of  studies 
focusing on the VDR gene polymorphisms with suscep-
tibility to CKD or ESRD13-18. In this study, we reported 
that VDR was low expression in the serum of  ESRD 
patients. However, more studies should be performed to 
confirm it.
Furthermore, we also investigated the expression of  CY-
P24A1 in ESRD patients. There was also few study focus-
ing on it in ESRD patients. Amplified CYP24 expression 
was demonstrated in uremic rats, and it suggested that 
CYP24 had an etiological role in vitamin D insufficien-
cy commonly associated with CKD19. There was rarely 
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any study investigating its expression in ESRD patients. 
Our study reported that expression of  CYP24A1 was in-
creased in ESRD patients. However, the sample size was 
small, and more studies should be performed. 
Interestingly, we also found that VDR was negatively cor-
related with CYP24A1 in ESRD patients. There was also 
scarce reports to study this investigation in ESRD pa-
tients. However, the detailed mechanism should be stud-
ied in the further. 
To sum up those mentioned above, we drew the conclu-
sion that VDR levels were reduced and CYP24A1 levels 
were increased in patients with ESRD, and VDR levels 
were negatively correlated with CYP24A1 levels. How-
ever, the sample size in our study was small and the sub-
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